Ruxolitinib Vs Best Available Therapy in Patients With Steroid-Refractory/Dependent Chronic GRAFT-VS-HOST Disease (CGVHD): Subgroup Analyses of Overall Response Rate in The Phase 3 Reach3 Trial

Sadeleştirilmiş öğe sayfası
dc.contributor.authorLocatelli, Franco
dc.contributor.authorPolverelli, Nicola
dc.contributor.authorRam, Ron
dc.contributor.authorHashmi, Shahrukh K.
dc.contributor.authorChakraverty, Ronjon
dc.contributor.authorMiddeke, Jan Moritz
dc.contributor.authorMusso, Maurizio
dc.contributor.authorGiebel, Sebastian
dc.contributor.authorUzay, Ant
dc.contributor.authorAyuk, Francis Ayuketang
dc.contributor.authorZuckerman, Tsila
dc.contributor.authorFukushima, Kentaro
dc.contributor.authorVallejo, Juan Carlos
dc.contributor.authorPidala, Joseph
dc.contributor.authorHamad, Nada
dc.contributor.authorMoiseev, Ivan
dc.contributor.authorBonifazi, Francesca
dc.contributor.authorApte, Shashikant
dc.contributor.authorLangmuir, Peter
dc.contributor.authorHollaender, Norbert
dc.contributor.authorGowda, Maanasa
dc.contributor.authorStefanelli, Tommaso
dc.contributor.authorLee, Stephanie J.
dc.contributor.authorZeiser, Robert
dc.contributor.authorTeshima, Takanori
dc.date.accessioned2025-10-16T15:19:14Z
dc.date.issued2021
dc.identifier.otherWOS:000668928500053
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/7305
dc.publisherSPRINGERNATURE
dc.sourceBONE MARROW TRANSPLANTATION
dc.titleRuxolitinib Vs Best Available Therapy in Patients With Steroid-Refractory/Dependent Chronic GRAFT-VS-HOST Disease (CGVHD): Subgroup Analyses of Overall Response Rate in The Phase 3 Reach3 Trial
dc.typeMeeting Abstract

Dosyalar

Koleksiyonlar

WOS